Lenacapavir, a long-acting injectable PrEP, requires two injections annually, marking a significant advancement in HIV ...

FAYETTEVILE, N.C. (WTVD) -- Fayetteville native John Rowell calls the FDA's approval of the first injectable treatment for HIV pre-exposure prevention, PrEP, "monumental." The FDA said the injectable ...

A study suggests twice-yearly Yeztugo offers HIV prevention without adversely affecting gender-affirming care.

A drug currently used to treat certain HIV infections has also, on Wednesday, received approval from the US Food and Drug Administration to be used to prevent HIV. Gilead Sciences, maker of the drug, ...

Gilead Sciences’ pre-exposure prophylaxis (PrEP) formula of lenacapavir has been approved in the UK as a preventative option for HIV, offering patients a twice-yearly injection to reduce the risk of ...

In a new brief report, researchers caution against repeating past mistakes in HIV prevention, as high drug prices and insurance coverage issues have slowed uptake of long-acting, bimonthly injectable ...

Preventative therapies for HIV-1 (Human Immunodeficiency Virus type 1) have made leaps and bounds over the past decade. A once-daily pill named PrEP, or pre-exposure prophylaxis, has been a stalwart ...

The CDC made a strong recommendation based on a high certainty of evidence to use the long-acting injectable lenacapavir (Yeztugo) for HIV pre-exposure prophylaxis (PrEP), but will that ensure the ...

Dr Robert Mutumba, the head of the Aids Control Programme at the Ministry of Health, told Daily Monitor that Ugandans are ...

The first ever injectable drug that can prevent HIV has been approved for use in England and Wales. Subscribe to our newsletter for the latest sci-tech news updates. The drug, cabotegravir, would ...

For 27 years, Esther Shiyayo and her husband have navigated life in a discordant marriage. Esther is HIV‑positive while he remains HIV‑negative. To maintain his status, he faithfully took a daily dose ...